Communiqués Qiagen N.V.

Actions

QGEN

NL0015002SN0

Recherche biotechnologique et médicale

Marché Fermé - Nyse Autres places de cotation 22:00:02 13/05/2026			Varia. 5j.	Varia. 1 janv.
32,70 ^USD	-2,97%		-5,05%	-30,92%

13/05	Transcript : Qiagen N.V. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:00 PM
12/05	Qiagen N.V. propose un dividende annuel en numéraire, payable le 14 juillet 2026	CI

Communiqués

13/05	QGEN Investor Alert: Levi & Korsinsky Investigates Qiagen (QGEN) for Potential Securities Fraud	PR
12/05	Qiagen N : 2025 Annual Report 2025 Annual Financial Report	PU
12/05	Qiagen N : 2025 Remuneration Report	PU
12/05	QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting	BU
11/05	Qiagen N : Full Q1 2026 Results Investor Introduction	PU
07/05	Qiagen N : BofA Securities 2026 Healthcare Conference Investor introduction	PU
07/05	QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing	BU
07/05	Full Q1 2026 Results Presentation: Wednesday, May 6, 2026	PU
06/05	Qiagen: Q1 Earnings Snapshot	AQ
06/05	QIAGEN Reports Full Results for Q1 2026	BU
06/05	Qiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)	PR
30/04	Qiagen N : 2025 Annual Report 2025 IFRS Annual Report	PU
28/04	Preliminary Q1 2026 Results Conference Call Presentation: Tuesday, April 28, 2026	PU
28/04	Qiagen N : hoc Announcement according to Art. 17 Market Abuse Regulation	PU
27/04	Preliminary Q1 2026 Results Webcast Dial-in Details: Tuesday, April 28, 2026	PU
27/04	QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook	BU
27/04	QIAGEN N.V.: QIAGEN announces preliminary Q1 2026 results that achieved adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook by reducing expected net sales growth and adj. EPS	EQ
16/04	QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026	BU
15/04	Qiagen N : Sustainability Report (qiagen uk gender pay 2025 website v3)	PU
14/04	QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel	BU
01/04	Qiagen N : Sustainability Report (QIAGEN UK GENDER PAY 2025 website v3)	PU
20/03	Qiagen Announces Form 20-F Annual Report Filing for 2025 Results	BU
20/03	Qiagen N : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F)	PU
19/03	QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention	BU
12/03	Qiagen N : Sustainability Report (supplier code of conduct 2026)	PU